Transcript rodent disease

MRC Technology
an independent life science medical research charity
Biotech & Money 2016
Mr Andrew Mercieca, Director of Finance
[email protected]
www.mrctechnology.org
Who are MRC Technology?
A UK registered charity
Translating academic research
Life Science specialist
Founded in mid 1980s
25+ years in patenting,
licensing, drug discovery and
diagnostics research
Key Client: UK Medical
Research Council
Collaborating widely
UK, EC, US, China
A partner in Translation
Products on the Market
Tysabri®
Actemra®
Entyvio®
Keytruda®
MRC Technology Today
Ambition driven by our
Charitable ‘Objects’
Promote public benefit by
improving human health
Assisting the progress of the
scientific discoveries and
new technologies
Work with industry,
charities, universities and
health services
Perform R&D as needed to
accelerate the progress of
scientific discoveries
148 Staff
30 in ‘Technology Transfer’
74 ‘Drug Discovery’ scientists
10 ‘Diagnostics’ scientists
Financially self sufficient
Annual Revenue £28m
Annual Turnover £22.4m
R&D Spend
Drug Discovery ~£10m
Diagnostics ~£0.8m
What we offer
‘Translational’ Research
Collaborations:
Early stage drug discovery
Development of diagnostic
tests
‘Bridging the gap’ between
blue sky research and its
utilization
Commercialisation
Delivering therapies
Small Molecule Drug Discovery Team
Assay Development and Screening (Highly diverse experience)
HTS compatible assays, liquid handling robotics
Diverse compound library >120K; focused sets
Hit validation, IC50 data
Medicinal Chemistry (High level of “Pharma” experience)
Hit exploration and SAR development, computational chemistry
Tool compounds
Lead compounds for partnering
Early Pharmacology and ADME/DMPK
Cell based assays using pharmacodynamic read-outs
In house - Solubility, LogD, Microsomes, PAMPA, cytotoxicity
PK and other studies outsourced
Antibody Engineering Team
Capabilities
Generate mouse monoclonal antibodies
Humanise rodent antibodies (CDR Grafting)
Antibody engineering
Track record
Group established 1988
Fv
Fab
55+ antibodies successfully humanized
12 recombinant antibodies into clinic
6 currently in active clinical development
4 therapeutic antibodies approved
Marketed Products
Tysabri®; Actemra®; Entyvio®; Keytruda®
Fc
Diagnostics Development Team
Experienced team leader
Ex-Almac Diagnostics
10+ years in the industry
5 Assay development scientists
Currently recruiting
Investment in new equipment & systems
Liquid handling
qPCR
Quality Assurance
Building Networks with industry and clinicians
Translational Collaborations
Academic scientists/Institutions
Exciting blue sky research; Novel target, biomarker or test
Potential to address unmet clinical need
Biotechnology companies
early stage assets
limited resources
Pharmaceutical Companies
Risk sharing on interesting targets
with limited validation
‘Parked’ assets at ‘hit’ or
‘hit explosion’ stage
Projects We Are Looking For
Drug Targets
Novel targets or novel MOA
Clear disease association
Diagnostics
RNA/DNA –based assays in oncology,
infectious diseases and pharmacogenomics
Clear disease association but limited
validation
A range of enabling tools including:
Assays(s) and materials which may be used
to validate the opportunity
Disease models
What we will do: Drug Discovery
Work with Collaborator to deliver:
Composition of Matter IP
2 or more series of small molecules
Potent, selective, good DMPK/ADMET
properties
OR, a humanised rodent mAb with high potency,
expression, thermostability and low aggregation
Pre-clinical proof of concept in a disease model
Professional data package for commercialisation
Mitigates the investment risk to industry
Provides a solid platform for further pre-clinical
development
What we will do: Diagnostics
Work with Collaborator to:
Translate excellent research into
potential product
Quality controlled materials
Robust and reproducible assays
and protocols
Rigorous real–world testing
Deliver Professional data package
for commercialisation
Mitigates the investment risk to
industry
Provides a solid platform for clinical
development
Recent Drug Discovery Collaborations
Recently Partnered Projects
Antibodies
Immunotherapy
HCV
Fibrosis target
Small Molecules
Neurological target
Melanocortin receptors
(MCRs) programme
Current Partnering Opportunities
Target
Mode
Indication
Status
MNK1
Small Molecule
Cancer
Lead
optimisation
IL-17BR
Antibody
Fibrosis/
Allergic Asthma
Humanised
Kir7.1
Small Molecule
post-partum
haemorrhage
Screening/Hits
MCR2
Small Molecule
Cushing’s Disease Hit to Lead
MRCT: The Partner of Choice
Flexible business model
Proven track record
Fully collaborative
Flexible deal structures
Academic and commercial
partners
Translating Together
Contact [email protected]